Abstract
A flurry of reports indicates that we are entering a new phase in the development of mammalian target of rapamycin (mTOR)-based therapies for oncology. Here, we summarize exciting findings regarding mTOR signaling and the outlook for mTOR inhibitors as tools to study the mTOR pathway and as drugs in the clinic.
MeSH Terms
Everolimus
Humans
Immunosuppressive Agents/pharmacology
Mechanistic Target of Rapamycin Complex 1
Models, Biological
Multiprotein Complexes
Phosphatidylinositol 3-Kinases/metabolism
Protein Binding/drug effects
Protein Kinase Inhibitors/pharmacology
Protein Kinases/metabolism
Proteins
Signal Transduction/drug effects
Sirolimus/analogs & derivatives,pharmacology
TOR Serine-Threonine Kinases
Tacrolimus Binding Protein 1A/metabolism
Transcription Factors/metabolism
Chemicals
CRTC2 protein, human
Immunosuppressive Agents
Multiprotein Complexes
Protein Kinase Inhibitors
Proteins
Transcription Factors
ridaforolimus
temsirolimus
Everolimus
Protein Kinases
MTOR protein, human
Mechanistic Target of Rapamycin Complex 1
TOR Serine-Threonine Kinases
Tacrolimus Binding Protein 1A
Sirolimus
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Guertin David A
Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02141, USA.
Sabatini David M